Zhejiang Xianju Pharmaceutical

What Zhejiang Xianju Pharmaceutical does

Zhejiang Xianju Pharmaceutical Co., Ltd. (stock code 002332, Shenzhen Stock Exchange) is a China-based, publicly listed pharmaceutical manufacturer founded in 1972 that specializes exclusively in steroid hormone drugs. The company operates a vertically integrated business model spanning steroid active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), organized around three core product lines: corticosteroids and sex hormones; gynecology and reproductive health (contraceptives, progesterone, mifepristone); and perioperative anesthesia and muscle relaxants, plus adjacent respiratory and dermatology formulations. Its technology platform combines green chemical synthesis, bio-technology (40+ years of microbial transformation experience), and preparation R&D, supported by R&D partnerships with 20+ Chinese academic institutions and an international synchronous R&D operation.

The company monetizes through three revenue streams: (1) one-time-license sales of FDFs (including volume-based procurement, hospital, distributor, and direct-to-consumer e-commerce channels via Tmall and Ele.me); (2) one-time-license export sales of steroid APIs and intermediates to international pharmaceutical manufacturers across 50+ countries; and (3) professional services through CDMO/CMO custom development, registration, impurity, and safety assessment work — the latter anchored to its Italian subsidiary NewChem S.P.A. acquired in 2017. Manufacturing is structured as three China-based platforms plus two Italy-based plants, enabling both domestic volume-based procurement participation and EU/US regulatory supply. Customers span hospitals, distributors, international pharmaceutical manufacturers, and individual consumers; pricing is governed largely by national volume-based procurement tenders for domestic FDFs and by negotiated B2B contracts for APIs, CDMO, and exports.

The firm employs 3,200-3,600 staff across its headquarters in Xianju County (Taizhou), a production subsidiary in Linhai/Taizhou, a Hangzhou sales office, a Jiaxing R&D center, and the NewChem subsidiaries in Italy. Multiple products have won bids in national volume-based procurement rounds (5th, 9th, and 11th batches), key formulations pass consistency evaluations, and a wholly-owned subsidiary cleared an FDA on-site inspection in March 2025 — collectively evidencing the regulatory permissions that anchor the company's domestic and export businesses.

Name

Zhejiang Xianju Pharmaceutical

Legal name

浙江仙琚制药股份有限公司

Website

https://xjpharma.com

Company type

Public

Founded year

1972

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Zhejiang Xianju Pharmaceutical (SZSE: 002332) is a China-based, vertically integrated steroid hormone drug manufacturer producing APIs, intermediates, and finished dosage forms for gynecology, anesthesia, respiratory, and dermatology indications in 50+ countries.

Ownership category

akta.pro rank

Product category

Steroid Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Steroid pharmaceuticals
• Active pharmaceutical ingredients
• Finished dosage forms
• Gynecological and reproductive drugs
• Anesthesia muscle relaxants

Headquarters

HQ city

Taizhou

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Finished Dosage Formulations (FDFs): Production and sales of finished pharmaceutical preparations including gynecological products, anesthesia products, respiratory drugs, dermatological drugs, and generic drug products
2. Active Pharmaceutical Ingredients (APIs) & Intermediates: Production and sales of corticosteroid APIs, sex hormone APIs, progesterone APIs, and non-hormone series APIs, as well as intermediate products for pharmaceutical manufacturing
3. CDMO & CMO Services: Custom development, registration application and safety assessment of drug substances, intermediates and impurities. Services include laboratory development, process improvement, domestic and foreign registration applications, safety risk assessment, impurity study, and patent services

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Zhejiang Xianju Pharmaceutical researches, develops, manufactures, and sells steroid hormone medicines, including corticosteroid APIs and preparations, sex hormone drugs (gynecology and family planning drugs), anesthesia and muscle relaxant drugs, respiratory drugs, and dermatological drugs. The company operates a vertically integrated model spanning APIs and intermediates, finished dosage formulations, and CDMO/CMO services for drug substances, intermediates, and impurities. It is the only Chinese company integrating bulk pharmaceutical chemicals and preparations for steroid medicines.

Product overview

Zhejiang Xianju Pharmaceutical is a steroid hormone-focused pharmaceutical company with a vertically integrated business model combining bulk pharmaceutical chemicals (API) and finished dosage forms (FDFs). The company operates three core product lines: (1) FDFs including gynecological products (Yimaxin Progesterone Capsules, Clindamycin Phosphate Vaginal Gel, Levonorgestrel Enteric-coated Capsules/后定诺, Mifepristone Tablets, Misoprostol Tablets), anesthesia products (Rocuronium Bromide Injection, Sugammadex Sodium Injection, Ropivacaine Hydrochloride Injection, Flumazenil Injection), respiratory products (Yiqing Mometasone Furoate Nasal Spray/逸青, Tiotropium Bromide Powder for Inhalation/彼多益), and dermatology products (Mometasone Furoate Cream/芙美松, Mometasone Furoate Gel/精芙美松); (2) API & Intermediates covering corticosteroids (Prednisolone, Prednisolone Acetate, Dexamethasone, etc.), sex hormones (Estradiol, Testosterone compounds), and progesterone products (Progesterone, Mifepristone, Norethisterone); and (3) CDMO/CMO custom development services for drug substances and intermediates. The company also offers contract manufacturing and development services through its Italian subsidiary NewChem.

Differentiator

Problem solved

Functional benefit

Brands

• 后定诺 (Houdingnuo): Emergency contraceptive brand offering mifepristone and levonorgestrel products
• 逸青 (Yiqing)
• 芙美松 (Fumeisong)
• 益玛欣 (Yimaxin)
• 仙林 (Xianlin)

Products and services

• FDFs (Finished Dosage Forms / 制剂产品)
• APIs and Intermediates (原料药中间体)
• CDMO & CMO Services (定制开发)
• Yimaxin Progesterone Capsules (益玛欣)
• Clindamycin Phosphate Vaginal Gel (克林霉素磷酸酯阴道凝胶)
• Rocuronium Bromide Injection (罗库溴铵注射液)
• Yiqing Mometasone Furoate Nasal Spray (逸青)
• Tiotropium Bromide Powder for Inhalation (彼多益)
• Cisatracurium Besilate for Injection (注射用苯磺顺阿曲库铵)
• Ropivacaine Hydrochloride Injection (盐酸罗哌卡因注射液)
• Flumazenil Injection (氟马西尼注射液)
• Sugammadex Sodium Injection (舒更葡糖钠注射液)
• Mometasone Furoate Cream (芙美松)
• Mifepristone Tablets (含珠停)
• Misoprostol Tablets (米索前列醇片)
• Levonorgestrel Enteric-coated Capsules / Houdingnuo (后定诺)
• Prednisolone API (泼尼松龙)
• Prednisolone Acetate API (醋酸泼尼松龙)
• Drospirenone Ethinylestradiol Tablets (II) / Xiandingnuo (先定诺)
• Aciclovir Tablets (阿昔洛韦片)
• Prednisone Acetate Tablets (醋酸泼尼松片)
• Medroxyprogesterone Acetate Tablets (醋酸甲羟孕酮分散片)
• Finasteride Tablets (非那雄胺片)
• Testosterone Undecanoate Injection / Sitekeboji (思特博吉)
• Beraprost Sodium Tablets (贝前列素钠片)

Quantifiable outcome

• Ranked 67th among top 100 Chinese pharmaceutical companies in 2020, 62nd in 2021
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Six partnerships are on record, tiered major and core.

• Ele.me (饿了么医药)majorChannel Partner/ Reseller/ Distributor · 1 January 2025Strategic partnership with Ele.me for medical product distribution and delivery services in China. This e-commerce partnership enables direct-to-consumer sales of pharmaceutical products.
• NewChem S.P.A. (Italy)coreTechnology or Integration · 1 January 2017Acquired NewChem S.P.A. in Italy in 2017, establishing two standard bulk pharmaceutical chemicals plants in Europe. This acquisition expanded Xianju's global manufacturing footprint and provided access to international markets.
• Shanghai Institute of Organic Chemistry, Chinese Academy of SciencescoreStrategic or Co-development Partner · 1 January 1999Long-term partnership with Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences for steroid drug research and development. This is one of the key academic partnerships supporting Xianju's R&D capabilities.
• China Pharmaceutical UniversitycoreStrategic or Co-development Partner · 1 January 1999Strategic partnership with China Pharmaceutical University for new drug development and talent cultivation in steroid pharmaceuticals.
• Zhejiang UniversitymajorStrategic or Co-development Partner · 1 January 1999Partnership with Zhejiang University for research collaboration and development of steroid drug technologies.
• 20+ Domestic Research Institutes and UniversitiesmajorStrategic or Co-development Partner · 1 January 1999Long-term partnerships with more than 20 domestic prestigious research institutes and universities including Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Zhejiang University, and China Pharmaceutical University to bring in senior researchers and align with new drug development globally.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Organon & Co. Global specialty pharma focused on women's health, reproductive health, and biosimilars. Comparable to Xianju because both concentrate on contraceptives, hormone therapies, and reproductive-health pharmaceuticals with branded + generic portfolios.
• Theramex: Specialty pharma dedicated to women's health and hormone-related therapies. Closely comparable to Xianju's gynecology and reproductive-health segment (contraceptives, progesterone, HRT).
• Zhejiang Medicine Co., Ltd. (ZMC): Chinese listed pharmaceutical manufacturer producing APIs and finished formulations including vitamin and steroid-related products. Comparable as a domestic Chinese API + FDF manufacturer with overlapping therapeutic breadth.
• Huahai Pharmaceutical: Chinese listed pharma with significant API manufacturing, international regulatory filings (FDA, EU GMP), and CDMO services. Comparable as a Chinese peer competing in steroid and cardiovascular APIs with global registration depth.

Broad incumbents

• Cipla Limited: Indian multinational generic and specialty pharma with strong respiratory, dermatology, and women's health portfolios. Comparable in therapeutic categories (respiratory, dermatology, gynecology) and emerging-market export model.
• Lupin Limited: Indian multinational with strengths in women's health, respiratory, and complex generics/API manufacturing. Comparable as an API-plus-finished-dose manufacturer serving regulated and emerging markets.
• Dr. Reddy's Laboratories: Global Indian pharma with API + generics + CDMO services. Comparable to Xianju's integrated API/FDF/CDMO model and emerging-markets export footprint.
• Shanghai Pharmaceuticals Holding: Large Chinese state-owned pharma group with broad API, formulation, and distribution operations. Comparable as a domestic Chinese competitor in hospital tenders and VBP bidding across multiple therapeutic areas.

Regional players

• Tianjin Pharmaceutical Group: Major Chinese state-owned pharmaceutical group with broad steroid and hormone manufacturing capabilities. Comparable as a domestic Chinese competitor in steroid APIs and hormone formulations.

Emerging players

• Curia (formerly Albany Molecular Research / AMRI): Global CDMO offering custom API development and manufacturing. Comparable as a competing CDMO/CMO service provider leveraging steroid and small-molecule capabilities for pharma clients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zhejiang-xianju-pharmaceutical-co-ltd-

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhejiang Xianju Pharmaceutical